{
    "eid": "2-s2.0-85116805560",
    "title": "Generalized bullous fixed drug eruption after Oxford\u2013AstraZeneca (ChAdOx1 nCoV-19) vaccination",
    "cover-date": "2022-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "K. Wantavornprasert",
        "N. Noppakun",
        "J. Klaewsongkram",
        "P. Rerknimitr"
    ],
    "citedby-count": 12,
    "ref-count": 5,
    "ref-list": [
        "Fixed drug eruptions: an update, emphasizing the potentially lethal generalized bullous fixed drug eruption",
        "Fixed drug eruption after pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b combined vaccine in an infant",
        "SARS-CoV-2 mRNA vaccine-associated fixed drug eruption",
        "Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine",
        "Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Skin and Allergy Research Unit"
    ]
}